Status:
RECRUITING
Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
INSERM SC10-US19
Conditions:
HPV Infection
Anal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incide...
Detailed Description
The study aims to enrol 80 to 100 participants in French clinical centres. All the participants have participated to the IPERGAY HPV substudy. The study proposes to evaluate the cumulative incidence ...
Eligibility Criteria
Inclusion
- Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
- Informed and written signed consent
- Participant with regular health insurance
Exclusion
- Participant under guardianship or curatorship
- Participant with free State medical assistance
- Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06522256
Start Date
March 20 2025
End Date
July 30 2027
Last Update
December 4 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Croix Rousse - SMIT
Lyon, France, 69004
2
Hôpital Saint-Louis - SMIT
Paris, France, 75010
3
Hôpital Tenon - SMIT
Paris, France, 75020